Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus TACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus TACE.
DIETHYLSTILBESTROL vs TACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
TACE (Transcatheter Arterial Chemoembolization) is not a drug but a procedure combining intra-arterial chemotherapy and embolization. Chemotherapeutic agents (e.g., doxorubicin, cisplatin) are delivered directly to tumor-feeding arteries, inducing cytotoxicity, while embolic agents (e.g., lipiodol, microspheres) occlude blood flow, causing ischemia and enhancing drug retention.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
Transarterial chemoembolization (TACE) with doxorubicin: 50-75 mg/m² or up to 150 mg total dose, administered via hepatic artery injection, repeated every 4-6 weeks as tolerated.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Variable depending on the drug; for doxorubicin, terminal half-life is 24-36 hours, clinically relevant for systemic toxicity.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
TACE is not a specific drug but a procedure (transarterial chemoembolization). The chemotherapeutic agents used (e.g., doxorubicin, cisplatin, mitomycin C) are typically eliminated via hepatic metabolism and biliary excretion, with renal excretion as a minor route (<10% for doxorubicin).
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."